Market News How it works Learn FAQ
| RCT 0.0796 4.60% | NU 12.69 -16.29% | EWZ 34.43 -19.16% | BBD 2.935 -27.89% | TGL 0.2399 8.31% | AZTR 1.6199 126.56% | ITUB 7.75 -19.86% | NVD 3.9801 -5.01% | XP 15.9 -47.71% | SRTM 0.2985 -30.63% | WFF 0.0918 14.75% | SHFS 0.0943 -28.78% | SPCX 148.07 0.39% | PBR 22.515 -13.93% | SOXL 92.02 10.12% | VALE 11.96 -3.55% | CLRO 5.015 54.31% | INTC 91.38 5.08% | TSLL 10.875 11.42% | NVDA 216.37 2.56% | GCDT 0.1444 -18.00% | NOK 8.735 7.31% | NWGL 0.089 8.54% | BITO 10.66 -1.57% | SOXS 47.14 -10.14% | CRWV 56.4528 4.09% | RWM 14.485 -0.45% | JBLU 2.345 -10.67% | GPUS 0.1808 7.05% | ABEV 2.835 -14.09% | TSLG 5.44 11.70% | SGRY 23.245 47.59% | AAL 12.2501 1.16% | IREN 25.945 4.18% | INTR 4.6799 -34.91% | SBS 4.69 -26.72% | QID 14.175 -2.58% | TQQQ 68.805 3.79% | RBNE 0.17 -10.53% | T 20.9 -0.14% | SPDN 8.485 -0.64% | TSLA 393.715 5.77% | RIG 6.455 0.70% | WULF 12.225 7.99% | NFLX 63.745 -3.20% | SID 0.9078 -23.07% | LUCD 0.52 26.52% | GRAB 2.692 -3.51% | XTND 2.235 26.27% | PLUG 1.39 0.72%
ATAtai Beckley Inc. logo

Atai Beckley Inc. (ATAI)

NASDAQ Global Market · Currency in USD
$7.35 ▲ +0.00 (+0.00%)
As of Sep 11, 9:30 AM ET. Market open.

Summary

Previous Close
$7.35
Open
$7.35
Day's Range
$7.35 – $7.35
52 Week Range
$3.27 – $7.45
Volume
0
Avg. Volume
11,455,912
Market Cap
$2.73B
Beta (5Y Monthly)
1.55
PE Ratio (TTM)
--
EPS (TTM)
-$1.85
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Sep 9, 2026
1y Target Est
$7.69

Profile: Atai Beckley Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
99
CEO
Srinivas G. Rao

Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.12 · Revenue est. $400.00K
DateEst.Actual
Aug 11, 2026-$0.11-$0.09Beat
May 12, 2026-$0.11-$0.08Beat
Mar 6, 2026-$0.12-$0.05Beat
Nov 12, 2025-$0.12-$0.28Miss
Aug 14, 2025-$0.12-$0.14Miss
May 14, 2025-$0.19-$0.15Beat

Analyst view

Consensus price target
$7.69 ▲ +4.6%
Range $7.45 – $8.00
Rating: Hold
Buy 0% · Hold 100% · Sell 0%

Get free alerts on ATAI and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.